Broadcast Date: March 8, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Since the first approval of a recombinant biopharmaceutical in 1986, Chinese hamster ovary (CHO) cells have become the industry workhorse for biologics production. While there have been dramatic improvements in multiple areas of cell line development (e.g., transfection and fed-batch process), the design of the vector still typically relies on a “one-size-fits-all approach”: the therapeutic molecule’s coding sequences are inserted into a fixed plasmid, which contains a small set of legacy genetic components. This rigid approach often results in a suboptimal expression for both monoclonal antibodies and complex modalities (e.g., bispecific antibodies), which can impede clinical development.

In this GEN webinar, we will hear about a new CHO platform that moves beyond the one-size-fits-all paradigm by tailoring vectors for each molecule to optimize expression. This novel platform integrates a glutamine synthetase (GS) knockout CHO host, a hyperactive transposase, libraries of characterized genetic elements to control cellular functions, and computational tools for rational vector design and multi-omics analysis. Collectively, these genetic and software tools have enabled: (1) the development of high-copy, high-expression producer lines with long-term stability, (2) fine-tuning of heavy/light chain expression and GS selection, and (3) machine learning-based optimization for increased translational efficiency, secretion, and cell growth. We present case studies highlighting the impact of these tools to optimize expression for both standard monoclonal and bispecific antibodies.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.


Asimov logo

Kevin Smith
Kevin Smith, PhD
Head of Technology Development
Asimov